TrialDiabetologia2013

Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.

K C Herold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.